​

eQcell is a clinical-stage regenerative medicine company founded on 15 years of scientific investigation into stem cells at the University of Guelph’s Ontario Veterinary College, ranked fifth in the world ahead of Cambridge, Edinburgh, Michigan State, Vetsuisse, and U. Copenhagen. The principal is the Immediate Past Chair and a founding member of the North American Veterinary Regenerative Medicine Association.

​

eQcell’s products are culture-expanded, adult and neonatal stromal cells, known as mesenchymal stromal cells (MSCs). The company has characterized its cells for novel cell-based therapies having developed allogeneic equine cord blood stem cells as well as canine adipose-derived MSCs.

​

eQcell has completed enrollment in two novel equine clinical trials in Canada and the USA, and are currently enrolling in one equine and one canine trial in Canada. These trials are designed to inform its pivotal trial anticipated for 2026 to proceed toward marketing approval for the commercialization of its innovative therapies in a diverse range of conditions within the scope of veterinary health. Together with academic partnerships, eQcell continues to conduct in vivo studies in both horses and dogs, utilizing its autologous and allogeneic MSCs. eQcell has an open INAD with the FDA to receive binding concurrence on its GMP manufacturing platform.

​

eQcell’s initial concentration in veterinary therapy is designed to most rapidly achieve marketing approval to address the emerging veterinary regenerative market as well as to generate pre-clinical data leading to a scientifically and economically-effective pathway to translation into similar human applications; the company’s One Health approach from bench to stall to bed side.

​

eQcell currently offers MSC isolation services for Canadian veterinarians for autologous use of cells in horses and dogs, and individual autologous cell banking of equine
cord blood MSCs.